贵州三力制药股份有限公司（以下简称"公司"）于2024年9月12日召开了第四届董 事会第四次会议，审议通过了《关于以集中竞价交易方式回购公司股份方案的议 案》。同意公司使用自有资金通过集中竞价交易方式进行股份回购，回购股份将全部用 于后期实施员工持股计划或股权激励计划，回购资金总额不低于人民币8,000.00万 元（含），不超过人民币12,000.00万元（含），回购价格不超过人民币17.85元/股（含） ，回购期限自公司董事会审议通过回购股份方案之日起12个月内。具体内容详见公司 在上海证券交易所网站（www.sse.com.cn）披露的《贵州三力制药股份有限公司关 于以集中竞价交易方式回购公司股份方案的公告暨回购报告书》（公告编号： 2024-054）。 证券代码：603439 证券简称：贵州三力 公告编号：2025-038 贵州三力制药股份有限公司 关于股份回购进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2024/9/13 | | | | | | --- | -- ...

Core Viewpoint - The company has announced a profit distribution plan for the fiscal year 2024, which was approved at the annual shareholders' meeting on May 17, 2025 [1]. Distribution Plan - The profit distribution will be based on a total share capital of 409,802,216 shares, with 4,982,200 shares excluded from the distribution due to being held in a repurchase account, resulting in 404,820,016 shares eligible for distribution [2]. - Each eligible share will receive a cash dividend of 0.34 yuan (including tax), totaling 137,638,805.44 yuan (including tax) to be distributed [2]. Calculation of Ex-Dividend Price - The ex-dividend reference price will be calculated using the formula: Ex-dividend reference price = [(Previous closing price - Cash dividend) + (Subscription price × Change in circulating shares ratio)] / (1 + Change in circulating shares ratio) [3]. - The cash dividend per share, after dilution adjustment, is approximately 0.3359 yuan per share [3]. Dividend Distribution Method - Cash dividends for unrestricted circulating shareholders will be distributed through the China Securities Depository and Clearing Corporation Limited, Shanghai Branch [6]. - Shareholders who have not completed designated trading will have their dividends held by the clearing company until they complete the necessary transactions [6]. Taxation Details - For individual shareholders holding unrestricted circulating shares, dividends are subject to different tax treatments based on the holding period, with a maximum tax rate of 20% for shares held for less than one month [8]. - For shares held for more than one year, dividends are exempt from personal income tax [8]. - For foreign institutional investors, a 10% withholding tax will apply, resulting in a net cash dividend of 0.306 yuan per share [9]. Contact Information - For inquiries regarding the profit distribution, shareholders can contact the Securities Division at 0851-38113395 [11].

Core Viewpoint - Guizhou Sanli Pharmaceutical Co., Ltd. is implementing a differentiated dividend distribution plan due to the repurchase of shares and the cancellation of certain restricted stocks, ensuring compliance with relevant laws and regulations [2][7]. Group 1: Reasons for Differentiated Dividend - The company plans to repurchase and cancel 60,000 restricted stocks from one employee who no longer qualifies for the incentive program due to resignation [3]. - Additionally, 732,000 restricted stocks from seven employees will be repurchased and canceled as the company's performance did not meet the conditions for the third release period of the 2021 incentive plan [3]. Group 2: Dividend Distribution Plan - The total share capital of the company is 409,802,216 shares, and the company will distribute a cash dividend of 3.40 yuan (including tax) for every 10 shares to eligible shareholders, adjusting the total distribution amount accordingly due to the repurchased shares [5][6]. - The total cash dividend to be distributed amounts to 137,638,805.44 yuan (including tax) [5]. Group 3: Calculation Basis for Differentiated Dividend - As of May 29, 2024, the closing price of the company's shares was 12.02 yuan per share, with a total of 4,982,200 shares in the repurchase account [6]. - The reference price for ex-dividend is calculated to be approximately 11.68 yuan per share, with a minimal impact of 0.0351% on the reference price due to the differentiated dividend distribution [6][7]. Group 4: Legal Compliance and Conclusion - The legal opinion confirms that the differentiated dividend distribution complies with the Company Law, Securities Law, and relevant regulations, and does not harm the interests of the company or its shareholders [7].

Core Points - Guizhou Sanli Pharmaceutical Co., Ltd. has announced a cash dividend distribution plan, with a cash dividend of RMB 0.34 per share, totaling RMB 137,638,805.44 (including tax) for the participating shareholders [1][2][4] - The total number of shares participating in the distribution is 404,820,016 shares after excluding 4,982,200 shares that do not participate due to being held in a repurchase account [2][3] - The record date for the dividend distribution is June 25, 2025, with the ex-dividend date also set for June 26, 2025 [3][4] Dividend Distribution Details - The cash dividend will be distributed to shareholders registered with China Securities Depository and Clearing Corporation Limited, Shanghai Branch, as of the close of trading on the record date [1][3] - The company will not issue bonus shares or increase capital through the dividend distribution, meaning the number of circulating shares will remain unchanged [2][3] - The reference price for the ex-dividend will be calculated based on the formula: (previous closing price - cash dividend) [2][3] Tax Implications - For individual shareholders holding shares for more than one year, the cash dividend is exempt from personal income tax, resulting in an actual distribution of RMB 0.34 per share [6] - For shares held for less than one year, the tax will be calculated upon transfer, with a 20% tax rate applicable for holdings of one month or less [6][7] - Qualified Foreign Institutional Investors (QFII) will have a 10% withholding tax applied, resulting in a net cash dividend of RMB 0.306 per share [7][8]

北京市中伦律师事务所 关于贵州三力制药股份有限公司 差异化分红事项的 法律意见书 二〇二五年五月 北京市中伦律师事务所 关于贵州三力制药股份有限公司 差异化分红事项的 2、本所律师根据《公司法》《证券法》《回购股份监管指引》等规定，针 对本法律意见书出具日前已经发生或存在的事实，严格履行了法定职责，遵循了 法律意见书 勤勉尽责和诚实信用原则，进行了充分的查验，保证本法律意见书所认定的事实 真实、准确、完整，所发表的结论性意见合法、准确，不存在虚假记载、误导性 陈述或重大遗漏，并承担相应法律责任； 3、公司已保证，其已向本所律师提供了出具本法律意见书所必需的全部事 实材料、批准文件、证书和其他有关文件，并确认：公司提供的所有文件均真实、 准确、合法、有效、完整，并无任何虚假记载、误导性陈述或重大遗漏，文件上 所有的签名、印鉴均为真实，所有的复印件或副本均与原件或正本完全一致； 4、对于本法律意见书至关重要而又无法得到独立证据支持的事实，本所律 师依赖于政府有关部门、司法机关、公司、其他有关单位或有关人士出具或提供 的证明、证言或文件出具法律意见； 法律意见书 致：贵州三力制药股份有限公司 根据贵州三力制药股份有 ...

证券代码：603439 证券简称：贵州三力 公告编号：2025-037 贵州三力制药股份有限公司 2024年年度权益分派实施公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗 漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例 A 股每股现金红利0.34元 相关日期 | 股份类别 | 股权登记日 | 最后交易日 | 除权（息）日 | 现金红利发放 | | --- | --- | --- | --- | --- | | | | | | 日 | | Ａ股 | 2025/6/25 | － | 2025/6/26 | 2025/6/26 | 差异化分红送转： 是 一、通过分配方案的股东大会届次和日期 根据《上海证券交易所上市公司自律监管指引第 7 号—回购股份》的规定， 公司存放于回购专用证券账户的股份不参与本次利润分配。公司本次不参与利润 分配的股份数4,982,200股（回购专用账户中的4,190,200股及待回购注销的792,000 股）。 3. 差异化分红送转方案： （1）差异化分红方案 公司本次利润分配实施时股本总数为 409,802,216 ...

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

Group 1 - Xiaofang Pharmaceutical announced a collaboration with Shanghai Skin Disease Hospital to develop a new traditional Chinese medicine for hair loss, Compound Cèbǎi Tincture, which is expected to be the first TCM formulation for hair loss in China [1] - Guizhou Sanli plans to invest 150 million RMB in a patent transfer and technical cooperation contract with Guangdong Pharmaceutical University for the development of a new TCM drug [1] - The technical cooperation will involve a total development cost of 100 million RMB for the research and development of SL&GDPU-001, a new TCM drug [2] Group 2 - Jichuan Pharmaceutical's actual controller, Cao Longxiang, transferred part of his equity in Jichuan Holdings to his son, Cao Fei, which is an internal family equity adjustment and will not affect the company's independence [2] - Junshi Biosciences received acceptance for the clinical trial application of JT118 injection, a vaccine aimed at preventing monkeypox virus infection, marking a significant step as no such vaccine has been approved in China [3] - Palin Bio announced that its controlling shareholder, Shengbang Yinghao, intends to transfer 21.03% of its shares to China National Pharmaceutical Group, which will result in a change of control [3] Group 3 - East China Pharmaceutical's subsidiary received FDA approval for the clinical trial of HDM1010 tablets, aimed at treating type 2 diabetes, enhancing the company's competitiveness in the endocrine field [4]

Group 1 - Guizhou Sanli plans to sign a technology transfer and development contract with Guangdong Pharmaceutical University, with a total contract amount of RMB 150 million [1] - The technology contract involves the transfer of a patent for the use of Jinlv Banfenghe in the preparation of drugs for liver injury prevention and treatment, along with other related patents [1][2] - The patent transfer was successfully completed for RMB 50 million, with the transaction taking place on June 11, 2025 [1] Group 2 - The contract stipulates an overall transfer fee of RMB 50 million for the patent rights, with an initial payment of RMB 5 million due within 10 working days after signing [2] - The total development cost for the technical cooperation is RMB 100 million, with payments to be made in installments based on contract terms [2]

Core Viewpoint - Guizhou Sanli Pharmaceutical Co., Ltd. plans to sign technology transfer and development contracts with Guangdong Pharmaceutical University to enhance its product portfolio and market competitiveness through collaboration in drug research and development [1][5]. Group 1: Contract Overview - The company intends to sign a technology transfer contract for a fibrosis invention patent, successfully acquiring it for RMB 50 million on June 11, 2025 [2][3]. - The total amount for the proposed technology contracts is RMB 150 million, which is close to the board's review and disclosure threshold, prompting the management to voluntarily disclose this information [2][5]. - The company held board meetings on June 12, 2025, to approve the contracts, which do not require shareholder approval or constitute a major asset restructuring [2][5]. Group 2: Contract Details - The technology transfer contract involves the transfer of rights for the invention patent related to liver protection and fibrosis treatment, with the company becoming the sole patent owner [3][4]. - The payment structure for the patent transfer includes an initial payment of RMB 5 million within 10 working days after signing, followed by milestone-based payments [3][4]. - The technology development contract focuses on the joint development of SL&GDPU-001, a new traditional Chinese medicine, covering non-clinical and clinical research phases [4][5]. Group 3: Impact on the Company - The collaboration aims to leverage the company's industrial capabilities and the university's research resources, aligning with the company's long-term strategic goals [5]. - The contracts are not expected to significantly impact the company's current financial status or operating performance, with future impacts dependent on the progress of the projects [5].